Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.
about
A comparative study of discriminating human heart failure etiology using gene expression profilesPharmacologic management of chronic reno-cardiac syndromeTherapeutic options for the management of the cardiorenal syndrome.Design of therapy for advanced heart failure.Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.Adaptation of renal function in heart failure.Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure.Durable left ventricular assist device therapy in advanced heart failure: Patient selection and clinical outcomesAdvanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.CKD as an underrecognized threat to patient safety.Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approachesRenal function, serum sodium level, and outcomes in hospitalized systolic heart failure patients: An analysis of the COAST study.Heart transplantation: who should be considered and when?Decision making in advanced heart failure: a scientific statement from the American Heart AssociationThe future is here: ventricular assist devices for the failing heart.Can we improve the treatment of congestion in heart failure?Can we prevent or treat renal dysfunction in acute heart failure?Renal function in advanced heart failure.Pharmacologic therapy for New York Heart Association class IV heart failure.Decision-making under uncertainty in advanced heart failure.Therapeutic adjustments in stage D heart failure: challenges and strategies.Pathophysiology and clinical evaluation of acute heart failure.Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy.Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction.Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond.Propensity to match or mismatch patients and therapies?Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.Medical management of advanced heart failure
P2860
Q24815374-19BB1422-173D-4871-9999-B61C9760C577Q26829812-73599D1D-ADD3-4B0C-B713-0699EFF7C2C0Q34442587-89B25C1D-F2A6-4FBD-BB11-F5BBA3D39543Q36046596-661E09D6-A4C9-4435-A0D4-5C3B928293B0Q36551356-6AE0B4FE-50B3-4854-81B0-C1EC0A702601Q36627825-681E5799-AA0F-4E27-8C4E-4C4E2E1A563DQ36720773-EB0D6DB5-8BD6-4398-BC7A-EA457D3F7393Q36776529-3BE4448F-09B7-4B45-B064-B5F4884FE61BQ36811824-60B85FE5-4C4C-4465-860C-795E1F5B1398Q37009412-1D3A1D08-880C-4C92-BF9E-92A5D566D868Q37140940-A1F49F1E-3F70-41D7-8FC6-C38A89ACD104Q37205117-5797C2DC-DD48-4B4F-BE55-2331C39A65F3Q37361521-70CDB758-8E66-4EAE-8796-4AB04B6A33BFQ37486284-2F0D8888-C97E-4565-97E3-E04DA440C351Q37599866-B4E09E7A-6D90-4682-A264-6054218E8770Q37845856-97149C9E-CD6F-4C4A-9380-2D36D35FDAF4Q37873812-4A408472-CC9D-4B7B-BC00-9B56C36ADF3EQ37905951-BEEE40C3-A594-48ED-9365-DC84CF923167Q37929864-6BAC57A1-2623-4F14-B3E0-0DBF75EFFC52Q38201299-09FC4F90-F9D0-423D-992B-E0B9D398CD07Q38267665-DB454391-588C-4151-8072-9C6E9251A118Q38586834-868E3F81-3289-488D-B87A-FBBF79E0165AQ40377138-BE538000-7881-486E-86B1-15218FE7073BQ41859441-401353B2-1B0A-4174-ACB3-BD1D4970C6B7Q44902895-CE89CCEA-CD3D-4ED4-84AE-3F52938C339FQ45140974-10BD9A70-D4E8-4091-9F03-57375CC8F1B1Q47550657-C280B4C3-FF3D-4387-ABA0-26D8C26BCDA7Q50062635-DE6BC7B4-FF0E-4792-82AD-DC5E02EA4FC0Q52684877-691606A2-A000-41AE-8A02-3282F4D0367BQ57396286-7136ED8B-39F8-4724-9DED-7B622909D142
P2860
Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Development of circulatory-ren ...... t failure and early mortality.
@en
Development of circulatory-ren ...... t failure and early mortality.
@nl
type
label
Development of circulatory-ren ...... t failure and early mortality.
@en
Development of circulatory-ren ...... t failure and early mortality.
@nl
prefLabel
Development of circulatory-ren ...... t failure and early mortality.
@en
Development of circulatory-ren ...... t failure and early mortality.
@nl
P2093
P1476
Development of circulatory-ren ...... t failure and early mortality.
@en
P2093
Anju Nohria
Eldrin Lewis
Gilbert Mudge
James Fang
John Jarcho
Lynne W Stevenson
Michael Givertz
Michelle Kittleson
Monica R Shah
Shelley Hurwitz
P304
P356
10.1016/S0735-1097(03)00417-0
P407
P577
2003-06-01T00:00:00Z